SCHEMBL1949598

SCHEMBL1949598

CC(C)OC(=O)COc1cccc(C=O)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.46
MAPT P10636 7/20 0.45
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
USP2 O75604 1/20 0.39
HPGD P15428 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 1/20 0.38
ESR1 P03372 1/20 0.38
TSHR P16473 3/20 0.38
TLR2 O60603 1/20 0.38
ERN1 O75460 1/20 0.38
TLR1 Q15399 1/20 0.38
TLR6 Q9Y2C9 1/20 0.38
HSD17B10 Q99714 2/20 0.37
MAPK1 P28482 2/20 0.37
STAT3 P40763 1/20 0.37
PLA2G1B P04054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8865140 0.86 PTGDR2 (0.62) PTGDR2MAPTALDH1A1KDM4EMEN1
SCHEMBL1948055 0.82 USP2 (0.58) PTGDR2MAPTALDH1A1KDM4EUSP2
SCHEMBL12283514 0.77 ALDH1A1 (0.44) PTGDR2ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL17156171 0.77 MAPT (0.55) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL11787849 0.76 MAPT (0.45) PTGDR2MAPTALDH1A1KDM4EMEN1
SCHEMBL12283962 0.75 ERN1 (0.43) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL1579244 0.75 ALDH1A1 (0.48) PTGDR2MAPTALDH1A1KDM4EMEN1
SCHEMBL14784683 0.73 MAPT (0.44) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1950408 0.73 ALDH1A1 (0.45) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL5790903 0.72 PTGDR2 (0.59) PTGDR2MAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507237-A1 IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-10-10 EP disclosed
WO-2011068233-A1 IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-06-09 WO disclosed
US-20110136801-A1 Novel Compounds DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136801-A1 Novel Compounds C1R, RB1, CNKSR1 PTGDR2 1385/4885MAPT 3434/4885ALDH1A1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.